Asia-Pacific startups like Shiftbio are leveraging extracellular vesicle (EV) technology for next-generation drug delivery systems. Shiftbio’s AI-powered nanoparticle design and manufacturing platform enables efficient targeting and delivery, exemplified by SBI-102, a lead candidate for liver cancer with regenerative properties. EVs offer advantages including low immunogenicity, enhanced biocompatibility, and the ability to cross biological barriers, positioning these companies at the forefront of drug delivery innovation in the region.